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Abstract
Background and objectives Intensive RRT may have adverse effects that account for the absence of benefit
observed in randomized trials of more intensive versus less intensive RRT. We wished to determine the asso-
ciation of more intensive RRT with changes in urine output as a marker of worsening residual renal function in
critically ill patients with severe AKI.
Design, setting, participants, & measurements The Acute Renal Failure Trial Network Study (n=1124) was a
multicenter trial that randomized critically ill patients requiring initiation of RRT tomore intensive (hemodialysis
or sustained low–efficiency dialysis six times per week or continuous venovenous hemodiafiltration at 35 ml/kg
per hour) versus less intensive (hemodialysis or sustained low–efficiency dialysis three times per week or con-
tinuous venovenous hemodiafiltration at 20 ml/kg per hour) RRT. Mixed linear regression models were fit to
estimate the association of RRT intensity with change in daily urine output in survivors through day 7 (n=871);
Cox regression models were fit to determine the association of RRT intensity with time to$50% decline in urine
output in all patients through day 28.
ResultsMean age of participants was 60615 years old, 72% were men, and 30% were diabetic. In unadjusted
models, among patients who survived $7 days, mean urine output was, on average, 31.7 ml/d higher (95%
confidence interval, 8.2 to 55.2 ml/d) for the less intensive group compared with the more intensive group
(P50.01). More intensive RRT was associated with 29% greater unadjusted risk of decline in urine output
of $50% (hazard ratio, 1.29; 95% confidence interval, 1.10 to 1.51).
Conclusions More intensive versus less intensive RRT is associated with a greater reduction in urine output
during the first 7 days of therapy and a greater risk of developing a decline in urine output of$50% in critically ill
patients with severe AKI.
Clin J Am Soc Nephrol 11: 1335–1342, 2016. doi: 10.2215/CJN.10991015
Introduction
Critically ill patients who develop AKI requiring RRT
have a high estimated mortality of approximately
50%–60% (1–3). The use of RRT in this clinical setting
is designed to optimize acid-base balance, small sol-
ute clearance, and volume control. Providing more
intensive RRT (via greater solute clearance as mea-
sured by urea kinetic modeling) was, therefore, hy-
pothesized to be beneficial (4–6). However, when
tested in subsequent larger randomized, controlled
trials, higher-intensity RRT in AKI has failed to im-
prove outcomes compared with standard intensity
therapy (7–9). A potential explanation for the absence
of benefit may be an increased risk of adverse events
associated with more intensive therapy. Enhanced
clearance of small solutes may result in electrolyte
depletion (8,10), and enhanced removal of antibiotics
may result in decreased efficacy in the treatment of
infections (11,12). In addition, untoward hemodynamic
effects, such as greater frequency of intradialytic
hypotension (IDH; e.g., precipitated by rapid changes
in plasma osmolality) (8), may exacerbate organ ische-
mia, including hypoperfusion of the already injured
kidney parenchyma.
Preservation of urine output is an important prog-
nostic indicator in the setting of AKI. Patients with
AKI who develop reduced urine output have sub-
stantially greater risk of death (13–16), longer dura-
tion of dialysis dependence (16), and longer hospital
stay (13) compared with those who do not. Reduced
urine output in patients with AKI requiring RRT may
indicate a greater severity of kidney injury with less
likelihood of renal recovery (17), greater associated
mortality (14), and predisposition to complications
related to volume management (18,19). No study to
our knowledge has tested whether more intensive
RRT in AKI leads to a reduction in urine output, a
potential surrogate marker of residual renal function.
To test the hypothesis that more intensive RRT may
cause adverse effects on urine output, we performed a
*Renal Division,
Department of
Medicine, Brigham
and Women’s
Hospital, Boston,
Massachusetts;
†Harvard Medical
School, Boston,
Massachusetts;
‡Department of
Biostatistics, School
of Nursing, University
of North Carolina at
Chapel Hill, Chapel
Hill, North Carolina;
§Department of
Biostatistics, Harvard
School of Public
Health, Boston,
Massachusetts; |Renal
Section, Veterans
Affairs Pittsburgh
Healthcare System,
Pittsburgh,
Pennsylvania; and
¶Renal-Electrolyte
Division, Department
of Medicine,
University of
Pittsburgh School of
Medicine, Pittsburgh,
Pennsylvania
Correspondence:
Dr. Finnian R.
Mc Causland, MRB-4,
Brigham and
Women’s Hospital,
Boston, MA 02446.
Email: fmccausland@
partners.org
www.cjasn.org Vol 11 August, 2016 Copyright © 2016 by the American Society of Nephrology 1335
post hoc analysis of the Acute Renal Failure Trial Network
(ATN) Study to determine the association of more inten-
sive versus less intensive RRT with postrandomization
changes in urine volume.
Materials and Methods
Study Design and Population
The ATN Study was a prospective, multicenter, ran-
domized clinical trial of more intensive (hemodialysis [HD]
or sustained low–efficiency dialysis six times per week or
continuous venovenous hemodiafiltration at 35 ml/kg
per hour) versus less intensive (HD or sustained low–
efficiency dialysis three times per week or continuous
venovenous hemodiafiltration at 20 ml/kg per hour)
RRT in critically ill patients with a clinical diagnosis con-
sistent with acute tubular necrosis (n=1124). Details of
the study design have been previously reported (8,20).
Notable exclusion criteria included a baseline serum cre-
atinine .2 mg/dl for men and .1.5 mg/dl for women,
AKI felt to not be caused by acute tubular necrosis, more
than one HD treatment or .24 hours of continuous RRT
before randomization, and expected survival ,28 days
because of an underlying terminal chronic condition.
Survival to day 7 (n=871) was a prespecified requirement
for our primary post hoc analyses because of the compet-
ing risk of mortality in critically ill patients with AKI. The
study protocol pertaining to these post hoc analyses was
deemed exempt under 42 CFR §46.101(b)(4) by the Part-
ners Healthcare Institutional Review Board.
Exposures and Outcomes
The exposure of interest was the randomized treatment
assignment of more intensive versus less intensive RRT.
The primary outcome of interest was the rate of change in
daily urine output in patients who survived from random-
ization through (and including) day 7 (n=871). Additional
analyses were performed to determine the association of
more intensive versus less intensive RRT with the need for
continued RRT at days 28 and 60. The secondary outcome
was the time to $50% decline in daily urine output in the
complete cohort from randomization through day 28
(n=1103). The majority of urine outputs (95.7%) were re-
corded as timed 24-hour collections during each study
day. For those with collection periods other than 24 hours
(median =12 hours; interquartile range [IQR], 7–16 hours),
the estimated daily output was extrapolated according
to the following equation: daily urine output = (urine
volume/hours of collection) 324.
Study Data
All study data in the ATN Study were recorded on case
report forms and submitted to a central data coordinating
center. Demographic data (sex, race, and age), comorbid
data (ischemic heart disease, congestive heart failure,
peripheral vascular disease, hypertension, stroke, liver
disease, diabetes, malignancy, baseline cardiovascular
[CV] sequential organ failure assessment [SOFA] score,
and 24-hour urine volume), and anthropometric data
(weight and height) were recorded at baseline for all
participants. The original ATN Study defined baseline
oliguria as an average urine output ,20 ml/h over a
24-hour period. However, in light of the observed distribu-
tion of the baseline 24-hour urine volumes, we defined base-
line oliguria as a 24-hour urine volume ,110 ml/d (the
25th percentile). Postrandomization physiologic data, in-
cluding urine volume, BUN, the CV component of the
SOFA score, and net fluid balance (total intake 2 [total
output + ultrafiltration]), were recorded on days 1–14, 21,
and 28.
Statistical Analyses
Continuous variables were examined graphically and
recorded as means (6SDs) for normally distributed data or
medians (with IQRs) for non–normally distributed data.
Comparisons were made using t tests or Wilcoxon rank
sum tests as appropriate. Categorical variables were exam-
ined by frequency distribution and recorded as propor-
tions, and comparisons were made using the chi-squared
test. To model the daily urine output for the primary anal-
yses, the following unadjusted linear mixed model was fit
(model 1), where Yijk denotes the urine output for patient k
in treatment group i (i=1→ less intensive RRT; i=2→more
intensive RRT) on day j: E[Yijk]=m. . .+ti+a3j+gi3
j+dj(k)+«ijk. In this model, m represents the intercept, ti
represents a fixed effect for treatment i, a represents a
fixed effect for day j, gi represents an interaction effect
for treatment i and day j, dj(k) represents a random effect
of day j nested within patient k (to account for correlation
among urine output levels within each patient across
time), and «ijk represents an error term for Yijk, which is
normally distributed with mean =0 and variance of s2«. We
also fit separate unadjusted models to assess each of the
following effects on daily urine output: (1) the interaction
between treatment assignment and treatment modality
and (2) the interaction between treatment assignment
and baseline urine output. Subsequently, a multivariable
model was fit (model 2) that adjusted for the following
baseline variables: sex, race (black versus nonblack), age,
ischemic heart disease, congestive heart failure, peripheral
vascular disease, hypertension, stroke, liver disease, dia-
betes, malignancy, CV component of the SOFA score (0, 1,
2, 3, or 4), oliguria, weight, and height. All models were
implemented in SAS (SAS Institute Inc., Cary, NC) using
PROC GLIMMIX, where the Kenward–Roger denominator
degrees of freedom method was used. Analogous models
were fit for those who survived through day 28.
Exploratory models examining the daily rate of change
were fit by adjusting for the same covariates as model 2 in
addition to individual adjustment for time–varying cova-
riates of interest (for survivors through day 7). These pre-
specified covariates included daily measurement of BUN,
CV SOFA score, and net fluid balance. Logistic regression
models were subsequently fit to determine the unadjusted
and adjusted (model 2) associations of RRT intensity with
the need for continued RRT at days 28 and 60.
For analysis of the secondary outcome, unadjusted
and adjusted (model 2) Cox proportional hazards models
were fit to estimate the association of more intensive versus
less intensive RRT with time to decline in urine output
of $50%. Fixed effects with nominal two–sided P values
of ,0.05 were considered statistically significant. Analyses
were performed using SAS software, version 9.4 (SAS Institute
Inc.) and Stata MP13.1 (StataCorp., College Station, TX).
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Results
Of the 1124 individuals in the ATN Study, 871 survived
through day 7 and were included in our primary analyses.
Mean age was 59.6615.3 years old, 14.9% were black, and
30.4% were diabetic. The demographic and comorbid char-
acteristics of individuals according to randomized treat-
ment arms were comparable at baseline (Table 1).
During the first 7 days of the study, the average CV
SOFA score and ultrafiltration volume achieved by RRT
were similar between the treatment arms. BUN was lower
in the more intensive arm, whereas net fluid balance was
more negative in the less intensive arm (Table 2).
Rate of Change in Daily Urine Output from Randomization
through Day 7
Urine volume at the time of randomization was similar in
both groups (median =264 ml/d; IQR, 106–473 in the less
intensive group and median =274 ml/d; IQR, 110–489 in
the more intensive group; P difference =0.49). During the
initial 7-day period, the unadjusted mean urine output in-
creased by 23.2 (95% confidence interval [95% CI], 6.6 to
39.8) ml/d with less intensive therapy and decreased by
8.5 (95% CI, 225.2 to 8.1) ml/d with more intensive ther-
apy (Figure 1). The difference in the daily rate of change in
urine output was 31.7 (95% CI, 8.2 to 55.2) ml/d higher,
favoring the less intensive therapy arm. When adjusted for
baseline covariates (model 2), the mean urine output in-
creased by 26.6 (95% CI, 9.4 to 43.7) ml/d with less inten-
sive therapy and decreased by 9.7 (95% CI, 227.0 to 7.6)
ml/d with more intensive therapy. The difference was 36.3
(95% CI, 11.9 to 60.7) ml/d, favoring the less intensive
therapy arm. In exploratory analyses aimed at uncovering
potential pathway intermediaries, three prespecified time–
varying covariates (net daily fluid balance, BUN, and CV
component of the SOFA score) were added individually to
model 2. Each resulted in a modest attenuation of the ef-
fect estimate for the difference in daily rate of change com-
pared with model 2 alone (Table 3).
When the analyses were restricted to those who survived
through day 28, the unadjusted mean urine output increased
by 3.5 (95% CI,22.9 to 9.8) ml/d with less intensive therapy
and decreased by 2.7 (95% CI, 28.8 to 3.4) ml/d with more
intensive therapy. The difference was 6.2 (95% CI, 22.6 to
15.0) ml/d higher with less intensive therapy. When ad-
justed for baseline covariates (model 2), the mean urine out-
put increased by 4.6 (95% CI, 22.0 to 11.2) ml/d with less
intensive therapy and decreased by 1.6 (95% CI, 27.9 to
4.8) ml/d with more intensive therapy. The difference was 6.1
(95% CI, 23.0 to 15.3) ml/d higher with less intensive therapy.
There was no evidence for effect modification on the
basis of modality of RRT (P interaction .0.90). When base-
line urine output was considered as a continuous variable,
there was marginal evidence for the presence of effect
modification (P interaction =0.08). Therefore, exploratory
analyses were performed to assess the association of treat-
ment assignment in the subgroups of patients who were
oliguric and patients who were not oliguric. For those who
were oliguric at baseline, the adjusted difference (model 2)
in the daily rate of change in urine output was 11.4 ml/d (95%
CI, 217.0 to 39.8), in favor of the less intensive arm; for those
Table 1. Baseline characteristics of individuals who survive through day 7 according to RRT intensity randomized groups
Characteristic
RRT Intensity
P ValueaLess Intensive,
n=436
More Intensive,
n=435
Men, % 70.2 73.6 0.27
Age, yr 59.7615.4 59.5615.3 0.83
Black, % 14.7 15.2 0.84
Ischemic heart disease, % 24.1 22.0 0.48
Heart failure, % 26.5 24.5 0.51
Peripheral vascular disease, % 15.8 18.7 0.28
Hypertension, % 2.9 4.6 0.18
Diabetes, % 29.2 31.6 0.45
Stroke, % 9.0 10.8 0.39
Liver disease, % 17.1 14.2 0.24
Malignancy, % 15.6 18.0 0.36
Weight, kg 85.0618.7 84.1619.7 0.48
Height, in 68.063.9 68.163.8 0.70
CV SOFA score 2 (0–4) 2 (0–4) 0.19
Total SOFA score 14 (11–16) 14 (11–17) 0.26
Baseline 24-h urine volume, ml 264 (106–473) 274 (110–489) 0.49
Nonoliguric,b % 74.9 75.4 0.86
CV SOFA, cardiovascular component of the sequential organ failure assessment score at baseline; SOFA, sequential organ failure
assessment score.
aP value for difference; significance testing was by t test or Wilcoxon rank sum test for continuous variables or chi-squared test for
categorical variables. Continuous variables are presented asmeans6SDs if normally distributed andmedians (25th to 75th percentiles)
if non-normally distributed.
bOliguria was defined as baseline prerandomization 24-hour urine output ,110 ml/d.
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who were nonoliguric at baseline, the adjusted difference in
the daily rate of change was 45.7 ml/d (95% CI, 14.2 to 77.2),
in favor of the less intensive arm (Table 4).
Consistent with the results of the primary study (8), there
was no association of more intensive RRT with a greater odds
for continued RRT requirement at either day 28 (unadjusted
odds ratio [OR], 1.26; 95% CI, 0.96 to 1.64 and adjusted OR,
1.32; 95% CI, 0.98 to 1.77) or day 60 (unadjusted OR, 1.20; 95%
CI, 0.87 to 1.65 and adjusted OR, 1.26; 95% CI, 0.88 to 1.79).
Time to ‡50% Decline in Urine Output from
Randomization through Day 28
In unadjusted analyses, there was a 29% greater risk
of $50% decline in daily urine output (hazard ratio, 1.29;
95% CI, 1.10 to 1.51; P=0.001) in patients randomized to
more intensive versus less intensive therapy (Figure 2).
When adjusted for baseline covariates (model 2), the effect
estimate was accentuated (hazard ratio, 1.37; 95% CI, 1.15
to 1.63). The results were qualitatively similar when the
composite outcome of time to death or $50% decline of
urine output was considered (data not shown).
Discussion
In this post hoc analysis of the ATN Trial Study, we re-
port that more intensive RRT in critically ill patients with
AKI resulted in a greater reduction in the daily rate of
change in urine output than less intensive dosing of RRT
Figure 1. | Box plots of daily urine output according toRRT intensity. Less intensive is shown inwhite, andmore intensive is shown in gray. The top
line of each box represents the 75th percentile, the middle line represents the 50th percentile, and the bottom line represents the 25th percentile.
Table 2. Differences in physiologic parameters of interest in individuals who survived through day 7
Characteristic
RRT Intensity
P Value
Less Intensive More Intensive
No. of treatments 5 (3–7) 6 (6–7) ,0.001
CV SOFA score 2 (0–4) 1 (0–4) 0.07
BUN, mg/dl 48 (34–67) 35 (24–51) ,0.001
Ins 2500 (1530–3980) 2830 (1770–4397) ,0.001
Outs 722 (262–1600) 614 (200–1420) ,0.001
Urine 159 (35–530) 106 (20–365) ,0.001
UF volume, ml 1850 (524–3000) 1700 (500–3000) 0.22
Net balance, ml 2220 (21500–1301) 4 (21304–1712) ,0.001
Summary statistics were calculated by averaging the daily measurement of parameters of interest for each individual over the 7 study
days and are presented as medians (25th to 75th percentiles). Differences were assessed byWilcoxon rank sum tests. Ins indicate daily
fluid intake in milliliters. Outs indicate daily fluid loss (excluding urine and UF) in milliliters. UF volume indicates daily fluid loss
removed by RRT modalities in milliliters. Net balance indicates total intake 2 (total output + UF volume). CV SOFA, cardiovascular
component of the sequential organ failure assessment score; UF, ultrafiltration.
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during the first week of therapy but did not result in dif-
ferences in dialysis dependence at day 28 or 60. We also
report that patients randomized to more intensive therapy
had a greater risk of decline in urine output of $50%.
These results suggest that lower urine output is a potential
early adverse effect of more intensive RRT.
Before the availability of routine biochemical analyses,
urine output was the major parameter by which changes in
Table 3. Differences (less intensive RRT 2 more intensive RRT) in rate of change in daily urine output with individual additional
adjustment for prespecified time–varying covariates in individuals who survived through day 7
Model
Daily Rate of Change in Urine Output
Less Intensive
RRT
More Intensive
RRT
Difference
(Less Intensive 2More Intensive)
Unadjusted, n=871
Rate, ml/d (95%
confidence interval)
23.2 (6.6 to 39.8) 28.5 (225.2 to 8.1) 31.7 (8.2 to 55.2)
P value 0.01 0.31 0.01
Model 2, n=783
Rate, ml/d (95%
confidence interval)
26.6 (9.4 to 43.7) 29.7 (227.0 to 7.6) 36.3 (11.9 to 60.7)
P value 0.002 0.27 0.004
Model 2 and daily net
fluid balance, n=775
Rate, ml/d (95%
confidence interval)
14.8 (1.2 to 28.4) 218.2 (231.3 to 25.1) 33.0 (14.2 to 51.7)
P value 0.03 0.01 ,0.001
Model 2 and daily CV
SOFA score, n=776
Rate, ml/d (95%
confidence interval)
2.2 (213.9 to 18.2) 227.3 (242.7 to 211.9) 29.5 (7.5 to 51.5)
P value 0.79 ,0.001 0.01
Model 2 and daily
BUN, n=783
Rate, ml/d (95%
confidence interval)
26.8 (9.5 to 44.1) 24.3 (222.1 to 13.4) 31.2 (6.6 to 55.7)
P value 0.002 0.63 0.01
Model 2 was adjusted for baseline sex, race (black versus nonblack), age, ischemic heart disease, congestive heart failure, peripheral
vascular disease, hypertension, stroke, liver disease, diabetes, malignancy, cardiovascular component of the sequential organ failure
assessment score (CV SOFA) score (0, 1, 2, 3 or 4), oliguria, weight, and height.
Table 4. Analyses of the daily rate of change in urine output according to the presence or absence of baseline oliguria in individuals
who survived through day 7
Sub-Group
Daily Rate of Change in Urine Output
Less Intensive
RRT
More Intensive
RRT
Difference
(Less Intensive 2More Intensive)
Oliguria
(model 2), n=198
Rate, ml/d (95% CI) 29.9 (9.9 to 49.9) 18.5 (21.6 to 38.6) 11.4 (217.0 to 39.8)
P value 0.003 0.07 0.43
Nonoliguria
(model 2), n=585
Rate, ml/d (95% CI) 25.5 (3.3 to 47.6) 220.2 (242.6 to 2.2) 45.7 (14.2 to 77.2)
P Value 0.02 0.08 0.004
Estimates were adjusted for baseline sex, race (black versus nonblack), age, ischemic heart disease, congestive heart failure, peripheral
vascular disease, hypertension, stroke, liver disease, diabetes, malignancy, cardiovascular component of the sequential organ failure
assessment score (CV SOFA) score (0, 1, 2, 3 or 4), weight, and height. Oliguriawas defined as baseline prerandomization 24-hour urine
output ,110 ml/d. 95% CI, 95% confidence interval.
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kidney function could be assessed; it remains an important
clinical parameter in everyday practice. Several consensus
panels have incorporated lower thresholds of urine output
in the definition of AKI (e.g., RIFLE [21], AKI Network
[AKIN] [22], and Kidney Disease Improving Global Out-
comes [23]) in recognition of the association of decreased
urine output in critically ill patients with adverse out-
comes. For example, in 1977, Anderson et al. (13) studied
90 patients with AKI (defined as persistent rise in serum
creatinine .2 mg/dl despite corrective measures) and re-
ported that patients who were not oliguric had a signifi-
cantly shorter hospital stay, required RRT less frequently,
and had lower mortality than those with oliguria. More
recently, Oh et al. (16) examined urine output measure-
ments over the 6-hour period before the initiation of con-
tinuous RRT in 361 critically ill Korean patients. They
found that those with predialysis 6-hour urine outputs
above the median ($107 ml) had lower mortality in
both unadjusted and case mix–adjusted analyses. Similar
patterns of association with mortality have been reported
in studies from South America (15) and Canada (14).
Greater degrees of volume overload have been associ-
ated with a higher risk of adverse outcomes, including
greater risk of 60-day mortality (24,25), longer duration of
ventilator dependence (18,26), and slower recovery of re-
nal function in those with AKI requiring RRT (19). Of note,
although no randomized studies have been implemented
to test if earlier initiation of RRT for volume control is
beneficial (because volume removal by RRT may be offset
by decreases in urine output), there is biologic plausibility
to suggest that preservation of urine output may be a rea-
sonable clinical management goal. In our study, we found
that the intensity of RRT associated with modest but sig-
nificant differences in the rate of change in urine output,
with greater increases in the daily rate of change in urine
output reported in the less intensive arm. Although the
less intensive arm had a slightly more negative average
net fluid balance during the first 7 study days, in explor-
atory models, additional adjustment for time–varying net
fluid balance actually resulted in modest attenuation of
the effect estimates. This suggests that fluid status may
partly mediate the association of RRT intensity with
changes in urine volume but is not the major explanatory
variable.
An important factor that may contribute to differences in
urine output according to RRT intensity could be the
presence of more hemodynamic instability associated with
greater intensity or frequency of dialytic therapy. Indeed,
the ATN Study reported that IDH events requiring vaso-
pressor support or other interventions were more frequent
in the intensive RRT arm (8), largely as a result of the
greater absolute number of intermittent HD treatments
in this arm. In exploratory models, we noted that addi-
tional adjustment for time–varying CV SOFA scores
(a measure of hemodynamic stability) resulted in a modest
attenuation of the effect estimates for daily rate of change
in urine output. These observations raise the possibility
that IDH could confound or lie on the causal pathway
for the association of lower urine output with more inten-
sive dialytic therapy. Analogous evidence exists in a post
hoc analysis of patients on chronic HD from the Hemodi-
alysis Study, in whom we previously reported that higher
versus lower target Kt/V was associated with a greater
risk of IDH (27), which, has been associated with greater
decline in residual urine output by others (28).
The minimum daily urine output in humans with normal
kidney function is determined by (1) the obligate solute
excretion from byproducts of metabolism and (2) the max-
imum concentrating ability of the kidney. This equates to a
minimum urine output of approximately 400 ml/d, with
measurements below this having traditionally been defined
as oliguria, and measurements ,100 ml/d being defined as
anuria. (29,30) Thus, higher clearance of small solutes (partic-
ularly urea) by more intensive versus less intensive RRT in
Figure 2. | Kaplan–Meier survival estimates for the association of more intensive versus less intensive RRTwith the decline in urine output to
‡50% from baseline.
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the ATN Study (8) may have partially contributed to a lower
obligate urine volume (31,32). In our exploratory analyses,
we noted that adjustment for time-updated measurements
of BUN resulted in attenuation of the effect estimate for the
difference in daily rate of change in urine output, supporting
the notion that adjustment for BUN as a marker of solute
load resulted in a smaller difference in changes in urine out-
put between the less intensive and more intensive arms.
Again, analogous evidence exists in patients on chronic
HD, in whom more frequent HD (resulting in lower time–
averaged urea concentrations) has been reported to be asso-
ciated with a more rapid decline in urine output (33,34).
To assess if the association of RRT intensity with changes
in urine volume persists over time, the data were analyzed
in those who survived through day 28. In this case, there
were no notable differences, suggesting that RRT intensity
may have a greater influence on changes in urine output
earlier in the course of AKI in critically ill patients.
Supportive evidence for this assertion is provided by the
fact that the favorable associations with less intensive
therapy were more pronounced in those who were non-
oliguric at baseline (which we defined as baseline 24-hour
urine $110 ml/d) compared with those who were oliguric.
However, we found no association of more intensive ther-
apy with risk of persistent RRT requirement at day 28 or
60. Indeed, prior studies of strategies to augment urine
output with diuretics in patients with AKI have not been
shown to improve mortality or reduce the need for RRT
(35,36). However, we are cognizant of the fact that the
primary study was not powered for these post hoc sub-
group analyses, which should be interpreted as hypothesis
generating. Similarly, the analyses in the survivors
through day 28 and later may be subject to selection and
survivor biases.
The ATN Study afforded a unique opportunity to test the
effect of RRT intensity on changes in urine output, a
biologically plausible adverse effect of intensive RRT. The
major strength of our report is that the primary analyses
were performed according to the randomized treatment
assignments from the ATN Study, which limits confound-
ing by disease severity. Adjustment for potential con-
founding variables did not result in qualitative changes to
the patterns of association that we observed, which might
be expected from the balance in baseline covariates in
participants included in this analysis. Furthermore, our
results were consistent across the primary analysis
(change in urine output in survivors through day 7) and
in the secondary analysis (time to decline in urine output
of $50%). Limitations of this analysis include the post hoc
nature of the study, because the trial was not designed to
examine urine output as the outcome of interest,
and limitations in generalizability from a randomized,
controlled trial. Because of data limitations, we were
not able to adjust for dialysate sodium, temperature, or
changes in serum osmolality in relation to the timing
of dialytic therapies or dosage or duration of diuretic
therapy.
In conclusion, we report that the use of more intensive
RRT is associated with a decline in the daily rate of change
in urine output during the first week of therapy among
critically ill patients requiring RRT initiation, consistent
with a potentially early adverse effect of more intensive
RRT on residual renal function. Additional studies should
identify the mechanistic basis for our findings. Identifying
the optimal RRT strategy in AKI has the potential to
improve the outcomes of hundreds of thousands of patients
annually and should be a major focus of investigative
efforts in critical care nephrology.
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